Type 1 Diabetes Therapeutics
1. Inpefa patent expiration
Treatment: Reduction of risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardi...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8476413 | LEXICON PHARMS INC | Sulfanyl-tetrahydropyran-based compounds and methods of their use |
May, 2028
(2 years from now) | |
| US7781577 | LEXICON PHARMS INC | Inhibitors of sodium glucose co-transporter 2 and methods of their use |
May, 2028
(2 years from now) | |
| US8217156 | LEXICON PHARMS INC | Solid forms of (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol and methods of their use |
Oct, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 26, 2028 |
Drugs and Companies using SOTAGLIFLOZIN ingredient
NCE-1 date: 27 May, 2027
Market Authorisation Date: 26 May, 2023
Dosage: TABLET
More Information on Dosage
INPEFA family patents
2. Symlin patent expiration
Treatment: Treatment of diabetes with an amylin agonist; Treatment of diabetes with an amylin agonist, including with insulin; Use of an amylin agonist to reduce gastric motility and treat post prandial hypergly...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5814600 | ASTRAZENECA AB | Method and composition for treatment of insulin requiring mammals |
Sep, 2015
(10 years ago) | |
| US5686411 | ASTRAZENECA AB | Amylin agonist peptides and uses therefor |
Mar, 2019
(6 years ago) | |
| US6608029 | ASTRAZENECA AB | Methods for regulating gastrointestinal motility |
Sep, 2013
(12 years ago) | |
| US6114304 | ASTRAZENECA AB | Methods for regulating gastrointestinal motility |
Sep, 2017
(8 years ago) | |
Drugs and Companies using PRAMLINTIDE ACETATE ingredient
Market Authorisation Date: 25 September, 2007
Dosage: INJECTABLE
More Information on Dosage
SYMLIN family patents